Search company, investor...

Predict your next investment

Takeda Pharmaceutical company logo
Corporation
HEALTHCARE | Pharmaceuticals / Drugs
takeda.com

Investments

27

Portfolio Exits

15

Partners & Customers

10

Service Providers

1

About Takeda Pharmaceutical

Takeda Pharmaceutical (TYO: 4502) (NYSE: TAK) is a research-based, pharmaceutical company. The company offers oncology, gastroenterology, neuroscience, rare diseases, vaccines, and plasma-derived therapies. Takeda Pharmaceutical was founded in 1781 and is based in Tokyo, Japan.

Headquarters Location

2-1-1 Nihonbashihonmachi, Chuo-ku

Tokyo, 103-8668,

Japan

+81 (0)3 3278 2111

Want to inform investors similar to Takeda Pharmaceutical about your company?

Submit your Analyst Briefing to get in front of investors, customers, and partners on CB Insights’ platform.

Research containing Takeda Pharmaceutical

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned Takeda Pharmaceutical in 4 CB Insights research briefs, most recently on Oct 28, 2022.

Latest Takeda Pharmaceutical News

Adoptive Cell Therapy Market Market will generate new growth opportunities 2023-2030 | GSK, AstraZeneca Plc, Merck, Dey.

May 4, 2023

News Provided By Share This Article Adoptive Cell Therapy Market Adoptive cell therapy (ACT) is a type of immunotherapy in which T cells are given to a patient to help the body fight diseases, such as cancer. BURLINGAME, CALIFORNIA, UNITED STATES, May 4, 2023 / EINPresswire.com / -- Adoptive Cell Therapy Market Size Projections : The global adoptive cell therapy market is estimated to be valued at US$ 4,932.5 million in 2022 and is expected to exhibit a CAGR of 21.5% during the forecast period (2023-2030). T cells, a class of immune cells, are given to a patient as part of adoptive cell therapy (ACT), a form of immunotherapy, to aid the body in fighting diseases like cancer. Chimeric antigen receptor (CAR) T cells, T cell receptor (TCR) T cells, tumour infiltrating lymphocytes (TILs), and natural killer (NK) cells are examples of adoptive cell treatment types. Adoptive cell therapy uses a large number of immune cells that have been generated in a lab before being given to the body to combat cancer. Immune cells that naturally recognise melanoma can be employed in some cases, but they can also be altered to recognise and destroy melanoma cells. T-cell transfer therapy and cellular immunotherapy are additional names for adoptive cell therapy. [140+ Pages Research Study] Coherent Market Insight has released a new research study titled Adoptive Cell Therapy Market is growing rapidly, which signifies a strong interest in Adoptive Cell Therapy research as we enter 2023. Today’s business leaders face an endless stream of decisions around target markets, pricing, promotion, distribution channels, and product features and benefits. They must account for all the factors involved, and there are market research studies and methodologies strategically designed to capture meaningful data to inform every choice. Ask Us to Get Your Sample Copy Of The Report, Covering TOC and Regional Analysis @ https://www.coherentmarketinsights.com/insight/request-sample/4957 Note – Updated Version 2023 is available (The sample of this report is readily available on request. The report sample contains a brief introduction to the research report, a Table of Contents, a Graphical introduction of regional analysis, Top players in the market with their revenue analysis, and our research methodology.) Our Sample Report May Includes: • 2030 Updated Report Introduction, Overview, and In-depth industry analysis. • 100+ Pages Research Report (Inclusion of Updated Research). • Provide Chapter-wise guidance on Requests. • 2023 Updated Regional Analysis with Graphical Representation of Size, Share & Trends • Includes Updated List of tables & figures. • Updated Report Includes Top Market Players with their Business Strategy, Sales Volume, and Revenue Analysis. Competitive Landscape: The given section on the global Adoptive Cell Therapy Market will include an extensive examination of the various players in this industry, their respective company overviews, an analysis of existing product portfolios, financials, etc. We even include a supply-chain analysis, a PEST analysis, market probability scenarios, Porter’s Five Forces analysis, and other related frameworks that are meant to aid in the expansion of your reputed organization. The specific application of these given findings allows all our clients to apply essential yet accurate data when formulating the most-suitable business strategies with the aim of improving their business’ footprint in this global industry. Top Key Players: GSK Plc, AstraZeneca Plc, Merck (Sigma-Aldrich), Dey Pharma, Grifols, S.A., Teva Pharmaceutical Industries Ltd, Baxter, Boehringer Ingelheim International GmbH, Kamada Ltd, Takeda Pharmaceutical Company Limited, LFB SA, Abeona Therapeutics, Alnylam Pharmaceuticals, Inc., Vertex Pharmaceuticals Incorporated, Kedrion S.p.A., and Arrowhead Pharmaceuticals, Inc. This report also splits the market by region: Americas, United States, Canada, Mexico, Brazil, APAC, China, Japan, Korea, Southeast Asia, India, Australia, Europe, Germany, France, UK, Italy, Russia, Spain, Middle East and Africa, Egypt, South Africa, Israel, Turkey, GCC Countries For Additional List and Detail Information on Key Players, Send Your Request for Custom Report@ https://www.coherentmarketinsights.com/insight/request-customization/4957 Research Methodology: • Prepared research questions for your market research participants • Lists of your primary competitors • Summarized your findings ➢ 𝐁𝐮𝐬𝐢𝐧𝐞𝐬𝐬 𝐝𝐞𝐬𝐜𝐫𝐢𝐩𝐭𝐢𝐨𝐧 – A detailed description of the company’s operations and business divisions. ➢ 𝐂𝐨𝐫𝐩𝐨𝐫𝐚𝐭𝐞 𝐬𝐭𝐫𝐚𝐭𝐞𝐠𝐲 – Analyst’s summarization of the company’s business strategy. ➢ 𝐒𝐖𝐎𝐓 𝐀𝐧𝐚𝐥𝐲𝐬𝐢𝐬 – A detailed analysis of the company’s strengths, weakness, opportunities and threats. ➢ 𝐂𝐨𝐦𝐩𝐚𝐧𝐲 𝐡𝐢𝐬𝐭𝐨𝐫𝐲 – Progression of key events associated with the company. ➢ 𝐌𝐚𝐣𝐨𝐫 𝐩𝐫𝐨𝐝𝐮𝐜𝐭𝐬 𝐚𝐧𝐝 𝐬𝐞𝐫𝐯𝐢𝐜𝐞𝐬 – A list of major products, services and brands of the company. ➢ 𝐊𝐞𝐲 𝐜𝐨𝐦𝐩𝐞𝐭𝐢𝐭𝐨𝐫𝐬 – A list of key competitors to the company. ➢ 𝐈𝐦𝐩𝐨𝐫𝐭𝐚𝐧𝐭 𝐥𝐨𝐜𝐚𝐭𝐢𝐨𝐧𝐬 𝐚𝐧𝐝 𝐬𝐮𝐛𝐬𝐢𝐝𝐢𝐚𝐫𝐢𝐞𝐬 – A list and contact details of key locations and subsidiaries of the company. ➢ 𝐃𝐞𝐭𝐚𝐢𝐥𝐞𝐝 𝐟𝐢𝐧𝐚𝐧𝐜𝐢𝐚𝐥 𝐫𝐚𝐭𝐢𝐨𝐬 𝐟𝐨𝐫 𝐭𝐡𝐞 𝐩𝐚𝐬𝐭 𝐟𝐢𝐯𝐞 𝐲𝐞𝐚𝐫𝐬 – The latest financial ratios derived from the annual financial statements published by the company with 5 years history. 𝐏𝐮𝐫𝐜𝐡𝐚𝐬𝐞 𝐓𝐡𝐢𝐬 𝐏𝐫𝐞𝐦𝐢𝐮𝐦 𝐑𝐞𝐩𝐨𝐫𝐭 𝐖𝐢𝐭𝐡 𝐔𝐩 𝐓𝐨 𝟐𝟓% 𝐎𝐅𝐅 @ https://www.coherentmarketinsights.com/insight/buy-now/4957 Purchasing the Adoptive Cell Therapy Market for the Following Reasons: ⋆The study examines emerging market trends as well as the likelihood that various trends will impact expansion. ⋆The analysis also discusses the factors, challenges, and opportunities that will have a significant impact on the global Adoptive Cell Therapy industry. ⋆ Technological tools and benchmarks that reflect the industry’s projected growth of the Adoptive Cell Therapy industry. ⋆ The research includes a detailed analysis of market statistics as well as historical and current growth conditions in order to provide futuristic growth estimates. ⋆The research includes a detailed analysis of market statistics as well as historical and current growth conditions in order to provide futuristic growth estimates. Table of Contents with Major Points: Introduction • Supply Chain Challenges • Potential opportunities due to COVID-19 outbreak TOC Continued…! Why Choose Coherent Market Insights? ☛ Identified business opportunities – Our market research report can be used to analyze potential markets and new products. It can give information about customer needs, preferences, and attitudes. Also, it compare products and services. ☛ A clear understanding of your customers – A market report gives company’s marketing department an in-depth picture about customers’ needs and wants. This knowledge can be used to improve products, prices, and advertising. ☛ Clear data-driven insights – Our Market research encompasses a wide range of activities, from determining market size and segment to forecasting demand, and from identifying competitors to monitoring pricing. All of these are quantified and measurable which means that gives you a clear path for building unique decisions based on numbers. About Us: Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients to achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having an office at global financial capital in the U.S., and sales consultants in the United Kingdom and Japan. Our client base includes players from across various business verticals in over 32 countries worldwide. We are uniquely positioned to help businesses around the globe deliver practical and lasting results through various recommendations about operational improvements, technologies, emerging market trends, and new working methods. Mr. Shah +1 206-701-6702

Takeda Pharmaceutical Investments

27 Investments

Takeda Pharmaceutical has made 27 investments. Their latest investment was in Cardurion Pharmaceuticals as part of their Series B on October 10, 2021.

CBI Logo

Takeda Pharmaceutical Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

10/28/2021

Series B

Cardurion Pharmaceuticals

$300M

No

6

6/30/2021

Convertible Note

Carmine Therapeutics

$5M

Yes

1

4/20/2021

Series A

Adaptate Biotherapeutics

$18M

Yes

2

4/1/2021

Seed VC

Subscribe to see more

$99M

Subscribe to see more

10

10/6/2020

Seed VC

Subscribe to see more

Subscribe to see more

10

Date

10/28/2021

6/30/2021

4/20/2021

4/1/2021

10/6/2020

Round

Series B

Convertible Note

Series A

Seed VC

Seed VC

Company

Cardurion Pharmaceuticals

Carmine Therapeutics

Adaptate Biotherapeutics

Subscribe to see more

Subscribe to see more

Amount

$300M

$5M

$18M

$99M

New?

No

Yes

Yes

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

6

1

2

10

10

Takeda Pharmaceutical Portfolio Exits

15 Portfolio Exits

Takeda Pharmaceutical has 15 portfolio exits. Their latest portfolio exit was HilleVax on April 29, 2022.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

4/29/2022

IPO

HilleVax

$99M

Public

5

1/31/2022

Divestiture

Takeda Pharmaceutical - Gastrointestinal Line

$99M

1

7/31/2021

Spinoff / Spinout

HilleVax

$99M

1

9/17/2020

IPO

Subscribe to see more

$99M

Subscribe to see more

10

9/16/2020

Divestiture

Subscribe to see more

$99M

Subscribe to see more

10

Date

4/29/2022

1/31/2022

7/31/2021

9/17/2020

9/16/2020

Exit

IPO

Divestiture

Spinoff / Spinout

IPO

Divestiture

Companies

HilleVax
Takeda Pharmaceutical - Gastrointestinal Line
HilleVax

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

$99M

Acquirer

Public

Subscribe to see more

Subscribe to see more

Sources

5

1

1

10

10

Takeda Pharmaceutical Acquisitions

22 Acquisitions

Takeda Pharmaceutical acquired 22 companies. Their latest acquisition was Nimbus Lakshmi on December 13, 2022.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

12/13/2022

$99M

Acquired

6

1/10/2022

Series A

$99M

$18M

Acquired

11

10/27/2021

Other

$99M

Acquired

4

3/9/2021

Series B

Subscribe to see more

$99M

$99M

Subscribe to see more

10

4/16/2020

Subscribe to see more

$99M

Subscribe to see more

10

Date

12/13/2022

1/10/2022

10/27/2021

3/9/2021

4/16/2020

Investment Stage

Series A

Other

Series B

Companies

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

$99M

Total Funding

$18M

$99M

Note

Acquired

Acquired

Acquired

Subscribe to see more

Subscribe to see more

Sources

6

11

4

10

10

Takeda Pharmaceutical Partners & Customers

10 Partners and customers

Takeda Pharmaceutical has 10 strategic partners and customers. Takeda Pharmaceutical recently partnered with Adaptive Biotechnologies on April 4, 2023.

Date

Type

Business Partner

Country

News Snippet

Sources

4/12/2023

Licensor

United States

Adaptive Biotechnologies Announces Translational Collaboration with Takeda to Measure Minimal Residual Disease with Its clonoSEQ® Assay Across Its Hematologic Malignancy Pipeline

SEATTLE , April 12 , 2023 -- Adaptive Biotechnologies Corporation , a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease , today announced it has entered into a translational collaboration with Takeda to use its clonoSEQ Assay to assess minimal residual disease to facilitate the development and commercialization of Takeda 's pipeline of treatments for patients with lymphoid malignancies .

5

4/3/2023

Licensor

France

Innate Pharma Announces Exclusive License of Antibodies to Takeda for Celiac Disease Research Program

Innate Pharma S.A. is a trusted partner to biopharmaceutical companies such as Sanofi and AstraZeneca , as well as leading research institutions , to accelerate innovation , research and development for the benefit of patients .

2

1/23/2023

Licensor

Hong Kong

Takeda To Acquire Exclusive Worldwide (ex-China) License of HUTCHMED’s Fruquintinib, a Highly Selective, Oral VEGFR1/2/3 Tyrosine Kinase Inhibitor

OSAKA , Japan & CAMBRIDGE , Mass. -- Takeda Pharmaceutical Company Limited today announced that it has entered into an exclusive licensing agreement with HUTCHMED Limited and its subsidiary HUTCHMED Limited , for the further development and commercialization of fruquintinib outside of mainland China , Hong Kong and Macau .

9

11/15/2022

Partner

United States

Subscribe to see more

Subscribe to see more

10

10/26/2022

Partner

United States

Subscribe to see more

Subscribe to see more

10

Date

4/12/2023

4/3/2023

1/23/2023

11/15/2022

10/26/2022

Type

Licensor

Licensor

Licensor

Partner

Partner

Business Partner

Country

United States

France

Hong Kong

United States

United States

News Snippet

Adaptive Biotechnologies Announces Translational Collaboration with Takeda to Measure Minimal Residual Disease with Its clonoSEQ® Assay Across Its Hematologic Malignancy Pipeline

SEATTLE , April 12 , 2023 -- Adaptive Biotechnologies Corporation , a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease , today announced it has entered into a translational collaboration with Takeda to use its clonoSEQ Assay to assess minimal residual disease to facilitate the development and commercialization of Takeda 's pipeline of treatments for patients with lymphoid malignancies .

Innate Pharma Announces Exclusive License of Antibodies to Takeda for Celiac Disease Research Program

Innate Pharma S.A. is a trusted partner to biopharmaceutical companies such as Sanofi and AstraZeneca , as well as leading research institutions , to accelerate innovation , research and development for the benefit of patients .

Takeda To Acquire Exclusive Worldwide (ex-China) License of HUTCHMED’s Fruquintinib, a Highly Selective, Oral VEGFR1/2/3 Tyrosine Kinase Inhibitor

OSAKA , Japan & CAMBRIDGE , Mass. -- Takeda Pharmaceutical Company Limited today announced that it has entered into an exclusive licensing agreement with HUTCHMED Limited and its subsidiary HUTCHMED Limited , for the further development and commercialization of fruquintinib outside of mainland China , Hong Kong and Macau .

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

5

2

9

10

10

Takeda Pharmaceutical Service Providers

1 Service Provider

Takeda Pharmaceutical has 1 service provider relationship

Service Provider

Associated Rounds

Provider Type

Service Type

Acq - P2P

Investment Bank

Financial Advisor

Service Provider

Associated Rounds

Acq - P2P

Provider Type

Investment Bank

Service Type

Financial Advisor

Partnership data by VentureSource

Takeda Pharmaceutical Team

37 Team Members

Takeda Pharmaceutical has 37 team members, including current Chief Executive Officer, President, Yasuchika Hasegawa.

Name

Work History

Title

Status

Yasuchika Hasegawa

Chief Executive Officer, President

Current

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Name

Yasuchika Hasegawa

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Work History

Title

Chief Executive Officer, President

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Current

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Compare Takeda Pharmaceutical to Competitors

Eurofarma Logo
Eurofarma

Eurofarma is a Brazilian pharmaceutical multinational that acts in the production and commercialization of medicines. The company has manufacturing plants in Latin America that produce for the following pharmaceutical segments: medical prescription, prescription drugs, generic, hospital, bids, oncology, services to third parties and veterinary.

BioCareSD Logo
BioCareSD

BioCare, founded in 1982, delivers specialty and therapeutic biological products to customers and provides customer-oriented solutions. It is based in Tempe, Arizona.

I
InDex Pharmaceuticals

InDex Pharmaceuticals develops drugs to increase the quality of life of patients suffering from immunological diseases. It is based in Solna, Sweden.

Vertex Pharmaceuticals Logo
Vertex Pharmaceuticals

Vertex Pharmaceuticals (NASDAQ: VRTX) develops small molecule drugs for serious diseases. The company's strategy is to commercialize its products both independently and in collaboration with major pharmaceutical companies. Vertex's product pipeline is focused on viral diseases, cystic fibrosis, inflammation, autoimmune diseases, cancer, and pain. Vertex co-discovered the HIV protease inhibitor, Lexiva, with GlaxoSmithKline.

Remedium Bio Logo
Remedium Bio

Remedium Bio is a Needham, Massachusetts-based gene therapy company focused on the development of treatments for a broad range of diseases.

Shionogi Logo
Shionogi

Shionogi (Tokyo: 4507.T) is a drug discovery-based pharmaceutical company. The company engages in the research, development, manufacture, and distribution of pharmaceuticals, diagnostic reagents, and medical devices. It offers Fetroja, a multidrug-resistant gram-negative bacterial infection treatment, Xofluza, an influenza virus drug, and Tivicay for HIV treatment. It also develops Symproic for opioid-induced constipation treatment. Shionogi was founded in 1878 and is based in Osaka, Japan.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.